[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595824":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":31,"locations":37,"responsibleParty":52,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DM with calcinosis disease severity assessment based on PA\u002FUS imaging","EXPERIMENTAL","Establish a non-invasive photoacoustic-ultrasound (PA\u002FUS) imaging evaluation method for DM with calcinosis to identify the characteristic PA\u002FUS manifestations of DM patients with different types of skin lesions, and use PAI to further assess the disease severity of DM patient.",[13],"Diagnostic Test: Multi-modal photoacoustic\u002Fultrasonic (PA\u002FUS) imaging system",{"label":15,"type":10,"description":16,"interventionNames":17},"DM patients with calcinosis planning to undergo drug treatment based on PA\u002FUS imaging","Patients over 18 years of age with histopathologically or clinically confirmed diagnoses based on the 2017 EULAR\u002FACR classification criteria who plan to undergo drug treatment.",[18],"Drug: Drug treatment",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","Multi-modal photoacoustic\u002Fultrasonic (PA\u002FUS) imaging system","The multi-modal PA\u002FUS imaging system is equipped with a handheld PA\u002FUS probe, and able to provide data of dual-wavelength PA imaging of DM skin lesions, in addition to real-time 2D conventioanl US imaging",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DRUG","Drug treatment","The multi-modal PA\u002FUS imaging system is equipped with a handheld PA\u002FUS probe, and able to provide data of dual-wavelength PA imaging of DM skin lesions, in addition to real-time 2D conventional US imaging. The histopathological biopsy results before and after treatment are combined as indicators for evaluating therapeutic efficacy and predicting treatment outcomes.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":35,"email":36},"Meng Yang, Doctor","CONTACT","8601060155493","yangmeng_pumch@126.com",[38],{"facility":5,"status":39,"city":40,"state":25,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Beijing","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":33,"role":34,"phone":51,"phoneExt":25,"email":36},"8601069155493",{"type":53,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100595824","photoacousticultrasound-imaging-in-patients-of-dermatomyositis-with-calcinosis-cutis-characteristic-findings-and-treatment-response-evaluation-100595824",false,"NCT07037472","Photoacoustic\u002FUltrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation","A Cohort Study Establishing a Standardized Scoring System in Dermatomyositis With Calcinosis Cutis and Assessing Treatment Response Via Multimodal Photoacoustic-Ultrasound Imaging","Inclusion Criteria:\n\n* All patients fulfilled the 2017 EULAR\u002FACR classification criteria for idiopathic inflammatory myositis. Of the adult DM patients enrolled, those were found to have calcinosis and were subsequently included in our analysis.\n* Among enrollees with idiopathic inflammatory myositis, patients with pathognomonic skin rashes were subclassified as DM or amyopathic DM patients based on the 2017 EULAR\u002FACR classification tree.\n* For patients without pathognomonic skin manifestations, DM was defined according to muscle biopsy.\n* Patients with amyopathic DM were grouped with DM patients.\n* Calcinosis diagnosis was based on clinical examination findings.\n\nExclusion Criteria:\n\n* Patients whose age at disease onset was \\\u003C18 years and those with overlap syndrome and\u002For IBM were excluded.","ALL","18 Years","80 Years",{"count":65,"type":66},100,"ESTIMATED","INTERVENTIONAL",[69],"NA","Photoacoustic imaging (PAI) is an emerging biomedical modality that integrates the advantages of optical contrast and ultrasound imaging depth. Capable of providing morphological, functional, and molecular information, PAI shows significant promise for visualizing human superficial tissue. The goal of this clinical trial is to build a PAI evaluation method for DM skin lesions, explore its application value in assessing DM disease severity and evaluation of treatment response. The main questions it aims to answer are:\n\n1. How to establish a non-invasive PA\u002FUS imaging evaluation method for DM skin lesions?\n2. Can PAI precisely assess DM disease severity?\n3. Can PAI systems predict the treatment response in DM with calcinosis cutis? Participants will receive regular PA\u002FUS imaging examinations during five stages of treatment (before treatment, 3 months, 6 months, 9 months and 12 months). And the effectiveness of PA\u002FUS in treatment response for DM at different time points will be evaluated.",[72,73],"Dermatomyositis","Dermatomyositis With Calcinosis Cutis",[72,75,76],"Dermatomyositis with Calcinosis cutis","Photoacoustic imaging","2025-06-16",{"date":79,"type":80},"2025-06-25","ACTUAL",{"date":82,"type":80},"2024-01-01",{"date":84,"type":66},"2028-12-31",{"name":5,"class":6},1]